8-K current report · filed Nov 12, 2026

Candel Therapeutics, Inc. (CADL) 8-K Current Report: November 12, 2026

Item 8.01CADL overview

Short answer

Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events). New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies.

Candel Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies
  • Prior 2025 ATM fully utilized, with approximately $50 million sold as of November 12, 2026
  • Potential equity issuance creates shareholder dilution and supplies additional capital for operations
  • Jefferies receives a 3.0% commission on gross proceeds from shares sold

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Candel Therapeutics, Inc. 8-K filings

Get the next CADL 8-K as it lands

Follow CADL for push alerts, or ask the research agent what this filing means.